GordonMD Global Investments LP
Clone Performance
Feb 2026–Sep 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Returns are unavailable when a held security or benchmark crosses a captured split without a certified price basis; the requested window is not shortened to hide it. It tracks 100% of reported value on average across 3 quarters. Past performance does not predict future results.
Portfolio Concentration
16 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $252,117,416 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | +5,903,039 | 10,024,909 | $30,174,976 | |
| ALLO | Allogene Therapeutics, Inc. | +3,868,000 | 5,298,000 | $11,019,840 | |
| TEVA | Teva Pharmaceutical Industries Ltd | +1,145,000 | 2,402,495 | $81,396,530 | |
| CLDX | Celldex Therapeutics, Inc. | +109,413 | 279,720 | $10,408,381 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | 3,127,000 | $10,131,480 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | 42,680 | $2,994,002 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| TEVA |
Teva Pharmaceutical Industries Ltd
Healthcare
|
Added | 2,402,495 | $81,396,530 | 32.29% | |
| KYTX |
Kyverna Therapeutics, Inc.
Healthcare
|
Held | 4,244,818 | $37,821,328 | 15.00% | |
| PYXS |
Pyxis Oncology, Inc.
Healthcare
|
Added | 10,024,909 | $30,174,976 | 11.97% | |
| VIR |
Vir Biotechnology, Inc.
Healthcare
|
Reduced | 1,353,552 | $13,792,694 | 5.47% | |
| ALLO |
Allogene Therapeutics, Inc.
Healthcare
|
Added | 5,298,000 | $11,019,840 | 4.37% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Added | 279,720 | $10,408,381 | 4.13% | |
| EDIT |
Editas Medicine, Inc.
Healthcare
|
NEW | 3,127,000 | $10,131,480 | 4.02% | |
| RARE |
Ultragenyx Pharmaceutical Inc.
Healthcare
|
Held | 289,101 | $9,653,082 | 3.83% | |
| BLCO |
Bausch & Lomb Corp
Healthcare
|
Held | 573,472 | $9,496,696 | 3.77% | |
| AMGN |
Amgen Inc
Healthcare
|
Held | 20,212 | $7,319,169 | 2.90% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
Held | 132,500 | $7,287,500 | 2.89% | |
| SION |
Sionna Therapeutics, Inc.
Healthcare
|
Held | 136,000 | $5,982,640 | 2.37% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Reduced | 723,185 | $4,924,889 | 1.95% | |
| INCY |
Incyte Corp
Healthcare
|
Held | 43,300 | $4,908,488 | 1.95% | |
| CRNX |
Crinetics Pharmaceuticals, Inc.
Healthcare
|
Held | 126,985 | $4,751,778 | 1.88% | |
| INSM |
INSMED Inc
Healthcare
|
Held | 28,587 | $3,047,945 | 1.21% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.